Challenges of PK/PD measurements in modern drug development

European Journal of Cancer

Volumn 38, Issue 16, 2002, Pages 2189-2193

  Workman, P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 AAG; 2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; MOLECULAR BIOLOGY; PATHOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0036840774     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00395-7     Document Type: Article

References (27)

1. Garrett M., Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur. J. Cancer. 35:1999;2010-2030.
2. Workman P. Scoring a bull's-eye against cancer genome targets. Curr. Opin. Pharmacol. 1:2001;342-352.
3. Workman P., Kaye S. A Trends Guide to Cancer Therapeutics, a supplement to Trends in Molecular Medicine, Vol. 8 No. 4. 2000;Elsevier Science, London.
4. Gibbs J B. Mechanism-based target identification and drug discovery in cancer research. Science 287, 1969-1973.
5. International Human Genome Sequencing Consortium Initial sequencing and analysis of the human genome. Nature. 409:2001;860-921.
6. Ventor JC, Adams MD, Myers EW et al. The sequence of the human genome. Science, 291, 1304-1351.
7. Futreal P.A., Ksprzyk A., Birney E., Mullikin J.C., Wooster R., Stratton M.R. Cancer and genomics. Nature. 409:2001;850-855.
8. Workman P, Graham MA, guest eds. Pharmacokinetics of Cancer Chemotherapy. Cancer Surveys, vol. 17. New York, Cold Spring Harbor Laboratory Press, 1993.
9. Clarke P., te Poele R., Wooster R., Workman P. Gene expression microarray analysis in cancer biology, pharmacology and drug development. progress and potential Biochem. Pharmacol. 62:2001;1311-1336.
10. Clarke P., Hostein I., Banerji U., Di Stefano F., Maloney A., Walton M., Workman P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene. 19:2000;4125-4133.
11. Hockel M., Vaupel P. Tumour hypoxia. definitions and current clinical, biologic, and molecular aspects J. Natl. Cancer Inst. 93:2001;266-276.
12. Semenza G. HIF-1 and tumour progression: pathophysiology and therapeutics. Trends Mol Med 2002, 8, S62-S67.
13. Brizel D.M., Scully S.P., Harrelson J.M.et al. Tumour oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
14. Aboagye E.O., Maxwell R.J., Horsman M.R.et al. The relationships between tumour oxygenation determined by oxygen electrodr measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. Br. J. Cancer. 77:1998;65-70.
15. Aboagye E.O., Maxwell R.J., Kelson A.B.et al. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumour hypoxia. Cancer Res. 57:1997;3314-3318.
16. Aboagye E.O., Kelson A.B., Tracy M., Workman P. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554, CRC 94/17). a non-invasive diagnostic probe for the measurement of tumour hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography Anticancer Drug Des. 13:1998;703-730.
17. Seddon BM, Maxell RJ, Honess DJ, et al. Validation of the fluorinated 2-nitroimidazole SR-4554 as a non-invasive hypoxia marker detected by magnetic resonance spectroscopy. Clin. Cancer Res 2002, 8, 2323-2335.
18. Aboagye E.O., Lewis A.D., Graham M.A., Tracey M., Kelson A.B., Workman P. The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554. Anticancer Drug Des. 11:1996;231-242.
19. Seddon B.M., Payne G.S., Simmons L.M.et al. Phase I pharmacokinetics and magnetic resonance spectroscopic study of the non-invasive hypoxia probe SR-4554. Proc. Am. Soc. Clin. Oncol. 21:2002;91b. (abstr 2176).
20. Maloney A., Workman P. HSP90 as a new therapeutic target for cancer therapy. the story unfolds Expert Opin. Biol. Ther. 2:2002;3-24.
21. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8(Suppl.):2002;S55-S61.
22. Banerji U., O'Donnell A., Scurr M.et al. A pharmacokinetically (PK)- Pharmacodynamically (PD) driven Phase I trial of the HSP90 molecular chaperone inhibitor 17- Allylamino 17- demethoxy geldanamycin (17AAG). Proc AACR. 43:2002;1352.
23. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 42:1998;273-279.
24. Solit D., Zheng F., Drobnjak M.et al. 17-Allylamino-17demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 8:2002;986-993.
25. Hostein I., Robertson D., Di Stefano F., Workman P., Clarke P.A. Inhibition of signal transduction by the Hsp90 inhibition 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 62:2001;4003-4009.
26. Chung Y.L., Troy H., Banerji U.et al. The pharmacodynamic effects of 17-AAG on HT23 xenogratfs in mice monitored by magnetic resonance spectroscopy. Proc AACR. 43:2002;73-74. (abstr 371).
27. Chung Y.L., Troy H., Judson I.R.et al. The effects of CYC202 in tumours monitored by magnetic resonance spectroscopy. Proc AACR. 43:2002;336. (abstr 1664).